Last Updated: August 8, 2026

Cediprof Inc Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for CEDIPROF INC

CEDIPROF INC has five approved drugs.

Summary for Cediprof Inc

US Patents:	0
Tradenames:	5
Ingredients:	5
NDAs:	5

Drugs and US Patents for Cediprof Inc

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-006	Mar 1, 2002	AB1,AB2,AB3	RX	No	No		⤷ Start Trial				⤷ Start Trial
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-009	Mar 1, 2002	AB1,AB2,AB3	RX	No	No		⤷ Start Trial				⤷ Start Trial
Cediprof Inc	DEXMETHYLPHENIDATE HYDROCHLORIDE	dexmethylphenidate hydrochloride	TABLET;ORAL	209211-002	Sep 19, 2018	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
Cediprof Inc	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	210754-003	Jul 5, 2022	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
Cediprof Inc	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	210754-002	Jul 5, 2022	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-001	Mar 1, 2002	AB1,AB2,AB3	RX	No	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Cediprof Inc

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-006	Mar 1, 2002	6,399,101	⤷ Start Trial
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-001	Mar 1, 2002	6,399,101	⤷ Start Trial
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-003	Mar 1, 2002	6,399,101	⤷ Start Trial
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-005	Mar 1, 2002	6,399,101	⤷ Start Trial
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-011	Mar 1, 2002	6,399,101	⤷ Start Trial
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-010	Mar 1, 2002	6,399,101	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Cediprof Inc

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.